61453-48-3

Usage

Uses

Used in Organic Synthesis:
Ethyl 5-(hydroxymethyl)-1H-pyrazole-3-carboxylate serves as a valuable intermediate in organic synthesis, facilitating the creation of a variety of complex organic molecules. Its functional groups allow for versatile chemical reactions, making it a key component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, ethyl 5-(hydroxymethyl)-1H-pyrazole-3-carboxylate is utilized as a starting material or a building block for the development of new drugs. Its pyrazole core and functional groups provide a foundation for the design of molecules with potential therapeutic effects, particularly given the known pharmacological properties of related pyrazole derivatives.
Used in Biological Activity Studies:
Due to its structural similarity to bioactive pyrazole compounds, ethyl 5-(hydroxymethyl)-1H-pyrazole-3-carboxylate is employed in biological assays to explore its potential as a lead compound for drug discovery. Research in this area may uncover novel pharmacological properties, such as antimicrobial, antiviral, or anticancer activities, expanding its utility in the medicinal chemistry domain.
Used in Industrial Applications:
Beyond its uses in synthesis and research, ethyl 5-(hydroxymethyl)-1H-pyrazole-3-carboxylate may find applications in various industrial processes. Its unique chemical properties could be harnessed in the development of new materials, catalysts, or as part of chemical processes in different sectors, such as the chemical, material science, or environmental industries.

Upstream product

• 623-73-4 diazoacetic acid ethyl ester 
• 107-19-7 propargyl alcohol 
• 71-43-2 benzene 

Downstream Products

• 71083-83-5 5-hydroxymethyl-1(2)H-pyrazole-3-carboxylic acid amide 
• 1401555-38-1 5-hydroxymethyl-1⁽²⁾H-pyrazole-3-carboxylic acid 

Relevant academic research and scientific papers

Novel quinazoline-containing compound, and intermediate and application thereof

The present invention discloses a quinazoline-containing compound having the formula (IA), (IB) or (IC), or a pharmaceutically acceptable salt or a prodrug molecule thereof. The compound is suitable for use as an Aurora kinase inhibitor and is thus suitable for the treatment of Aurora-mediated diseases characterized by excessive or abnormal cell proliferation, for example, cancer.

BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF

The invention provides novel compounds having the general formula (I): (I) wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

A facile synthesis of pyrazoles with multi-point structural diversity by 1,3-dipolar cycloaddition

We describe the synthesis of diverse pyrazoles by 1,3-dipolar cycloaddition of ethyl diazoacetate with various acetylenes in refluxing toluene. The product pyrazoles are useful starting points for preparing a diverse collection of trisubstituted pyrazole

Agonist lead identification for the high affinity niacin receptor GPR109a

A strategy for lead identification of new agonists of GPR109a, starting from known compounds shown to activate the receptor, is described. Early compound triage led to the formulation of a binding hypothesis and eventually to our focus on a series of pyrazole acid derivatives. Further elaboration of these compounds provided a series of 5,5-fused pyrazoles to be used as lead compounds for further optimization.

1,3-dipolar cycloaddition of ethyl diazoacetate to alkynes in the pores of zeolite NaY

Zeolite NaY promotes 1,3-dipolar cycloaddition of ethyl diazoacetate to alkynes having an electron-withdrawing group to afford the corresponding functionalized pyrazoles in high yields. The activation of the dipolarophile inside the pores of NaY is proposed based on the 13CMASNMR analysis. Copyright